|
|
|
Compass Therapeutics Inc (NASDAQ: CMPX) |
|
Compass Therapeutics Inc
Officers & Directors
Phil Ferneau Director Mary Ann Gray Director Ellen Chiniara Director James Boylan Director Carl L. Gordon Chair of the Board Thomas J. Schuetz Vice Chair of the Board Vered Bisker-Leib Chief Executive Officer and Director (Principal Executive Officer and Principal Financial and Accounting Officer) Richard Lindahl Director ,
Compass Therapeutics Inc currently has 39 employees.
News about Compass Therapeutics Inc Key Personnel |
BOSTON, Jan. 08, 2025 — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on the development of antibody-based therapeutics for various oncology-related diseases, has provided a corporate and financial update revealing formidable challenges intertwined with optimistic progress in their drug development pipeline.In their recent announcement, Compass Therapeutics reported its stock performance, which is currently trading at approximately 6.7% below its 52-week average. The company’s financial health reflects a troublesome trend, as they recorded a cumulative net loss of $48 million for the 12 months ending in the third quarter of 2024. This significant loss has r...
|
Compass Therapeutics Strengthens Leadership Team Amid Clinical Progress and Financial ChallengesBOSTON, Dec. 10, 2024 — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for oncology, has announced the appointment of Barry Shin as Chief Financial Officer, effective December 9, 2024. Mr. Shin brings over two decades of experience in the biopharmaceutical sector, holding various roles as a finance and operations executive, investment banker, and corporate advisor. His extensive background is seen as a strategic addition to Compass Therapeutics, especially as the company navigates the complexities of clinical deve...
|
Compass Therapeutics Appoints Dr. Thomas Schuetz as President and CEO, Marking a Significant Transition in Leadership
By
Boston, May 28, 2024 - Compass Therapeutics, Inc. (Nasdaq: CMPX), a renowned clinical-stage biopharmaceutical company dedicated to developing antibody-based therapeutics for various human diseases, has recently announced a momentous change in its leadership. The company s Board of Directors has appointed Dr. Thomas Schuetz, a highly accomplished and experienced professional, as the new President and Chief Executive Officer (CEO) of Compass Therapeutics, effective from May 28, 2024.
Dr. Schuetz, who has been serving as the President of Research and Development and Vice Chair of...
|
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
